Boston Common Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.68M	Buy	17,205 +1,124	+7%	+$524K	0.49%	64
2025 Q4	$7.29M	Sell	16,081 -24,818	-61%	-$10.7M	0.44%	70
2025 Q3	$16M	Sell	40,899 -5,164	-11%	-$2.16M	0.45%	76
2025 Q2	$20.5M	Sell	46,063 -4,900	-10%	-$2.26M	0.57%	59
2025 Q1	$24.7M	Buy	50,963 +671	+1%	+$313K	0.75%	41
2024 Q4	$20.3M	Buy	50,292 +26	+0.1%	+$12.1K	0.59%	59
2024 Q3	$23.4M	Buy	50,266 +13,008	+35%	+$6.25M	0.61%	53
2024 Q2	$17.5M	Sell	37,258 -2,061	-5%	-$895K	0.45%	86
2024 Q1	$16.4M	Sell	39,319 -16,038	-29%	-$6.78M	0.39%	97
2023 Q4	$22.5M	Sell	55,357 -2,670	-5%	-$986K	0.51%	74
2023 Q3	$20.2M	Sell	58,027 -1,210	-2%	-$423K	0.48%	78
2023 Q2	$20.8M	Sell	59,237 -15,499	-21%	-$5.22M	0.45%	83
2023 Q1	$23.5M	Sell	74,736 -2,568	-3%	-$770K	0.49%	72
2022 Q4	$22.3M	Buy	77,304 +2,027	+3%	+$618K	1.07%	27
2022 Q3	$21.8M	Buy	75,277 +20,308	+37%	+$5.84M	1.14%	27
2022 Q2	$15.5M	Buy	54,969 +23,085	+72%	+$6.18M	0.77%	44
2022 Q1	$8.32M	Buy	31,884 +844	+3%	+$200K	0.36%	89
2021 Q4	$6.82M	Sell	31,040 -505	-2%	-$98.2K	0.28%	99
2021 Q3	$5.72M	Sell	31,545 -169	-0.5%	-$33K	0.25%	100
2021 Q2	$6.39M	Buy	31,714 +7,635	+32%	+$1.6M	0.27%	94
2021 Q1	$5.17M	Buy	+24,079	New	+$5.29M	0.33%	89